Antibacterial and antiparasitic quinoxaline-2,3-diamine derivatives
By developing compounds of formulas (I), (II), and (III), the shortcomings of existing drugs in the treatment of schistosomiasis, liver fluke disease, and MRSA infection have been addressed, and effective treatment options for praziquantel and trichlorfonazole-resistant strains have been provided, enhancing the treatment options for parasitic and bacterial infections.
Patent Information
- Application Number
- CN202080061354.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-07-04
- Filing Date
- 2020-07-03
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-07-03
AI Technical Summary
In the current technology, there is a lack of effective treatments for schistosomiasis, liver fluke disease, malaria, and bacterial infections, especially methicillin-resistant Staphylococcus aureus (MRSA) infections. Furthermore, antimicrobial resistance is a serious problem, and existing drugs such as praziquantel and triclofenac have limitations and resistance issues.
A series of compounds, including those of formula (I), (II) and (III), have been developed as protein lysine methyltransferase inhibitors for the treatment of parasitic and bacterial infections, particularly schistosome larvae and MRSA that are unresponsive to praziquantel.
These compounds have shown effective therapeutic effects against schistosomes, liver flukes, malaria parasites, and a variety of bacteria, including strains resistant to praziquantel and triclofenac, providing new treatment options and reducing the risk of resistance.
Smart Images

Figure CN114514229B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to compounds useful for treating patients infected with pathogenic organisms. In particular, the present invention relates to compounds useful for treating parasitic and bacterial infections in humans and animals. Background Art
[0002] Pathogenic organisms such as parasites (e.g., multicellular worms and single-cell protozoa) and bacteria pose a huge risk to public health, especially in developing countries. For example, billions of people are thought to suffer from or be at risk of parasitic diseases. A particularly troublesome parasitic disease is schistosomiasis, caused by infection with parasitic flatworms known as schistosomes, which is considered by the World Health Organization to be the second most socioeconomically destructive human parasitic disease after malaria. Schistosoma haematobium, Schistosoma japonicum, and Schistosoma mansoni are the most prevalent and troublesome schistosome species, responsible for the majority of schistosomiasis cases.
[0003] Current schistosomiasis treatment and control efforts rely on treating high-risk populations with praziquantel, which remains the only drug available for schistosomiasis control. Despite its good efficacy and tolerability, praziquantel is ineffective against schistosome larvae. Reliance on a single drug to treat such a widespread disease also risks the development of drug resistance in these organisms.
[0004] Unfortunately, because schistosomiasis disproportionately affects developing countries, relatively little research has been done on new drugs in this area. Therefore, new drug treatments that can help combat schistosomiasis, particularly drugs that are effective against larval schistosomes, are urgently needed.
[0005] Another troublesome parasitic disease is fascioliasis, which affects both human and animal populations. Caused by Fasciola hepatica and Fasciola gigantica, fascioliasis costs the global beef, lamb and milk industries approximately $3.2 billion per year. Triclabendazole is the only commercially available drug that is effective against both larvae and adults of liver flukes. Unfortunately, triclabendazole-resistant liver flukes have been found in Africa, Asia, Australia, Europe, North America and South America. Because of this, there is an urgent need for new drugs that can supplement and / or replace triclabendazole.
[0006] Plasmodium is the most important parasitic disease in humans, malaria, which causes more than 500,000 deaths each year. The first-line chemotherapy for the most lethal Plasmodium (Plasmodium falciparum) involves artemisinin-based combination chemotherapy (ACT). Unfortunately, malarial parasites have developed resistance to this first-line treatment, especially in Southeast Asia. Therefore, people are looking for new drugs.
[0007] With regard to bacterial infections, antimicrobial resistance (AMR) in bacteria poses a serious and growing threat to human and animal health. Several commentators have suggested that the world may be facing a “post-antibiotic” era, in which society may no longer be able to rely on the effectiveness of antimicrobial agents and medicines to maintain public health. Some recent projections suggest that by 2050, unless new effective antimicrobial agents are developed, antimicrobial resistance will be the leading cause of mortality in the world population, causing approximately 10 million deaths per year. In addition to the human costs involved, such high mortality rates could result in a 2% to 3.5% annual reduction in GDP, equivalent to a loss of US$100 trillion per year due to AMR.
[0008] One strain of multidrug-resistant bacteria that is particularly prevalent in hospital-acquired infections and, more recently, community-acquired infections is methicillin-resistant Staphylococcus aureus, also known as MRSA. MRSA can cause skin infections and, more seriously, infections of the blood, lungs, or urinary tract. The continued increase in MRSA infections has led to longer hospital stays and increased mortality among patients.
[0009] Therefore, there is an urgent need to develop new antimicrobial agents with activity against MRSA-resistant and other Gram-positive bacteria.
[0010] WO 02 / 20463 A2 discloses compounds for modulating the farnesoid X receptor (FXR), which are useful for treating disorders such as obesity and diabetes. One specific compound disclosed in the document is compound 1:
[0011] Summary of the invention
[0012] Whether indicated herein or elsewhere, one of the objects of the present invention is to provide compounds or pharmaceutical compositions for treating patients (human or animal) infected with pathogenic organisms that solve at least one disadvantage of the prior art, or to provide alternatives to existing compounds. For example, an object of the present invention may be to provide compounds that are effective in treating schistosomiasis and / or bacterial infections. In addition, an object of the present invention may be to provide compounds that can additionally or alternatively be effective in treating hepatic fluke disease and / or malaria.
[0013] According to aspects of the present invention, there are provided compounds and uses as set out in the accompanying claims. Other features of the present invention will become apparent from the dependent claims and the following description.
[0014] According to a first aspect of the present invention, there is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in treating a patient infected with a pathogenic organism;
[0015]
[0016] wherein X and Y are each independently selected from C, N, O and S, provided that at least one of X and Y is N, O or S;
[0017] Where R 1 and R 2 each independently selected from C1-C8 alkyl, C1-C8 alkenyl, aryl, heteroaryl or alkylaryl groups, which may be optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxy, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups; or (CO)OR 13 or (CO)NHR 13 Group, where R 13 is selected from the group;
[0018] Wherein Z is selected from H, -CN, -NO2, -NR 3 R 4 、-NR 5 (CO)R 6 、C1-C4 alkyl、C1-C4 alkoxy、-(CO)WR 12 , hydroxyl, amino, thiol, chloro, fluoro, CF3, CHF2 or CH2F group; wherein W is a chemical bond, N or O, and wherein R 12 is selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0019] Where R 3 and R 4each independently selected from H, C1-C6 alkyl (optionally forming a ring), C1-C6 alkenyl, an aryl group, or a heteroaryl group, which is optionally substituted with one or more of a C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F group; or (CO)OR 14 or (CO)NHR 14 Group, where R 14 is selected from the group;
[0020] Where R 5 Selected from H, C1-C6 alkyl or C1-C6 alkenyl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0021] Where R 6 is selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups; or (CO)OR 15 or (CO)NHR 15 Group, where R 15 is selected from the group;
[0022] Where R 7 and R 8 Each independently selected from H or a C1-C4 alkyl group;
[0023] Where R 9 , R 10 and R 11 Each independently selected from H, C1-C4 alkyl, C1-C4 alkoxy, -(CO)WR 12 , hydroxyl, amino, thiol, chloro, fluoro, CF3, CHF2 or CH2F group; wherein W is a chemical bond, N or O, and wherein R 12 Selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted by one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups.
[0024] In structure (I), the dashed lines represent chemical bonds that may or may not exist depending on the characteristics of atoms X and Y. Thus, depending on the characteristics of atoms X and Y, R 7 and R8 May or may not exist.
[0025] In some embodiments, X and Y are both sulfur, R 7 and R 8 does not exist, and the chemical bond shown in structure (II) exists. Therefore, according to these embodiments of the first aspect of the present invention, there is provided a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof for use in treating a patient infected with a pathogenic organism;
[0026]
[0027] Where R 1 , R 2 , R 9 , R 10 , R 11 and Z are as defined above.
[0028] In some embodiments, X and Y are both nitrogen, R 7 and R 8 exists, and the chemical bond shown in structure (III) exists. Therefore, according to these embodiments of the first aspect of the present invention, there is provided a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof for use in treating a patient infected with a pathogenic organism;
[0029]
[0030] Where R 1 and R 2 Each independently selected from C1-C8 alkyl, C1-C8 alkenyl, aryl group, heteroaryl group or alkylaryl group, which is optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0031] Wherein Z is selected from -NO2, -NR 3 R 4 、-NR 5 (CO)R 6 、C1-C4 alkyl、C1-C4 alkoxy、-(CO)WR 12 , hydroxyl, amino, thiol, chloro, fluoro, CF3, CHF2 or CH2F group; wherein W is a chemical bond, N or O, and wherein R 12 is selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0032] Where R 3 and R 4 Each independently selected from H, C1-C6 alkyl (optionally forming a ring), C1-C6 alkenyl, aryl group, or heteroaryl group, which is optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0033] Where R 5 Selected from H, C1-C6 alkyl or C1-C6 alkenyl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0034] Where R 6 is selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0035] Where R 7 and R 8 Each independently selected from H or a C1-C4 alkyl group;
[0036] Where R 9 , R 10 and R 11 Each independently selected from H, C1-C4 alkyl, C1-C4 alkoxy, -(CO)WR 12 , hydroxyl, amino, thiol, chloro, fluoro, CF3, CHF2 or CH2F group; wherein W is a chemical bond, N or O, and wherein R 12 Selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted by one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups.
[0037] In the compounds of the first aspect, Z is suitably not H. Thus Z is suitably selected from -CN, -NO2, -NR 3 R 4 、-NR 5 (CO)R 6 、C1-C4 alkyl、C1-C4 alkoxy、-(CO)WR 12, hydroxyl, amino, thiol, chloro, fluoro, CF3, CHF2 or CH2F group; wherein W is a chemical bond, N or O, and wherein R 12 Selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted by one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups.
[0038] Suitably, R 9 , R 10 and R 11 Each is H, so the compound of the first aspect of the present invention may have the following structure (IV):
[0039]
[0040] The inventors have found that the compounds according to the first aspect can be used to treat patients infected with pathogenic organisms, in particular patients infected with schistosome parasites and bacteria such as Staphylococcus aureus (S. aureus), Mycobacterium smegmatis (M. smegmatis), MRSA, Enterococcus faecalis, Pseudomonas aeruginosa, Staphylococcus epidermidis (S. epidermidis) and Bacillus cereus (B. cereus). In particular, the compounds of this aspect can also be effective in treating larvae of schistosome parasites, for which current praziquantel treatment is ineffective. In addition, the compounds according to the first aspect can be used to treat humans or animals infected with Fasciola hepatica or Plasmodium parasites.
[0041] Furthermore, the compounds according to the first aspect may be used to treat humans or animals infected with Toxoplasma gondii.
[0042] With regard to bacteria, the compounds according to the first aspect may be particularly useful for treating Staphylococcus aureus, MRSA or Enterococcus faecalis, and are suitable for treating Staphylococcus aureus or MRSA.
[0043] The compounds according to the first aspect may act as inhibitors of protein lysine methyltransferases of pathogenic organisms. Thus, the compounds according to the first aspect may be used to treat diseases where inhibition of protein lysine methyltransferases of pathogenic organisms is beneficial, such as the infections discussed above.
[0044] Suitably, R 1 and R 2Each independently selected from C1-C8 alkyl, C1-C8 alkenyl, aryl group, heteroaryl group or alkylaryl group, which is optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, fluorine, chlorine, CF3, CHF2 or CH2F groups;
[0045] Suitably, R 1 and R 2 Independently selected from aryl groups or alkylaryl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, OH, NH2, SH, chlorine, fluorine, CF3, CHF2 or CH2F groups.
[0046] Alkylaryl refers to a group having an alkyl chain attached to an aryl group, such as a group having the following structure (V):
[0047]
[0048] wherein n is an integer of at least 1, and U and V represent optional substituents as mentioned above.
[0049] Suitably, R 1 and R 2 It has a structure of formula (V), wherein n is 0, 1, 2 or 3; wherein U and V are the above optional substituents at any position on the benzene ring.
[0050] Suitably, R 1 and R 2 is independently selected from an aryl group or an alkylaryl group, which is optionally substituted with one or more of a methyl, methoxy, OH, Cl, F or CF3 group. In this embodiment, R 1 and R 2 The optional substituent of the group can be on any carbon atom of the aryl group (or the aryl part of the alkylaryl group). Suitably, the aryl group is a phenyl ring. Suitably, the aryl group or the alkylaryl group is substituted by one or more of methyl, methoxy, OH, Cl, F or CF3 groups. Therefore, the compound of this first aspect suitably has structure (VI):
[0051]
[0052] Wherein n1 and n2 are each independently 0, 1 or 2;
[0053] wherein each U is selected from methyl, methoxy, OH, Cl, F or CF3;
[0054] wherein each V is optionally present, and when present, is selected from methyl, methoxy, OH, Cl, F or CF3;
[0055] Where Z is as defined above;
[0056] Where R 7 and R 8 Each independently selected from H or C1-C4 alkyl, suitably, wherein R 7 and R 8 All are H.
[0057] As shown in structure (VI), the U and V substituents may be present on any carbon atom of the benzene ring. The two benzene rings may have the same or different substituents. Preferably, the two benzene rings are the same (i.e., have the same substituents in the same position).
[0058] Suitably, the group R 1 and R 2 same.
[0059] Suitably, the group R 1 and R 2 n1 and n2 are each = 0; each U is selected from methyl, methoxy, OH, Cl, F or CF3; each V is optionally present, and when present, is selected from methyl, methoxy, OH, Cl, F or CF3; Z is as defined above; and R 7 and R 8 All are H.
[0060] Suitably, R1 and R2 are the same and are selected from:
[0061]
[0062] In the compound of the first aspect, suitably, R 7 and R 8 All are H.
[0063] In the compounds of the first aspect, Z may be selected from -NO2, -NR 3 R 4 、-NR 5 (CO)R 6 In some embodiments, Z is -NO2. In such embodiments, preferably, the group R 1 and R 2 n1 and n2 are each = 0; each U is selected from methyl, methoxy, OH, Cl, F or CF3; optionally, each V is present, and when present, is selected from methyl, methoxy, OH, Cl, F or CF3; Z is as defined above; and R 7 and R 8 All are H.
[0064] In some embodiments, Z is -NR 3 R 4or -NR 5 (CO)R 6 .
[0065] In which Z is -NR 3 R 4 In the embodiment, suitably, R 3 and R 4 Each is independently selected from H, C1-C6 alkyl (optionally forming a ring), C1-C6 alkenyl, an aryl group or a heteroaryl group, which is optionally substituted by one or more of a C1-C4 alkyl, a C1-C4 alkoxy, a C1-C4 alkylamino, a C1-C4 alkylthio, a hydroxyl, an amino, a thiol, a chlorine, a fluorine, a CF3, a CHF2 or a CH2F group.
[0066] Suitably, R 3 and R 4 Each is independently selected from H, C1-C6 alkyl (optionally forming a ring), C1-C6 alkenyl or aryl groups, which are optionally substituted with one or more of C1-C4 alkoxy, chlorine, fluorine, CF3, CHF2 or CH2F groups; suitably, R 3 and R 4 Independently selected from H, C1-C6 alkyl, optionally forming a ring, which is optionally substituted with one or more of C1-C2 alkoxy, F, Cl and CF3 groups.
[0067] In which Z is -NR 3 R 4 And R 3 and R 4 In the embodiment where Z is a C1-C6 alkyl group forming a ring, Z may therefore be a cyclic amino group, for example a group selected from the following:
[0068]
[0069] In which Z is -NR 5 (CO)R 6 In the embodiment, R 5 Suitably selected from H, C1-C6 alkyl or C1-C6 alkenyl; and R 6 Suitably selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups.
[0070] R 6Suitably selected from C1-C6 alkyl, C1-C6 alkenyl, aryl group or heteroaryl group, which is optionally substituted by one or more of C1-C4 alkyl, C1-C4 alkoxy, hydroxy, chlorine, fluorine, CF3, CHF2 or CH2F groups.
[0071] Suitably, R 5 It is H or methyl.
[0072] Suitably, R 6 is selected from a C1-C6 alkyl group, an aryl group or a heteroaryl group, which is optionally substituted by a C1-C2 alkyl group, a C1-C2 alkoxy group, OH, F, Cl or CF3 group.
[0073] Suitably, Z is selected from:
[0074]
[0075] In this embodiment, suitably, the group R 1 and R 2 n1 and n2 are each = 0; each U is selected from methyl, methoxy, OH, Cl, F or CF3; each V is optionally present, and when present, is selected from methyl, methoxy, OH, Cl, F or CF3; Z is as defined above; and R 7 and R 8 All are H.
[0076] In some embodiments, the compound of the first aspect is selected from compounds 1 and 4-21 described below.
[0077] According to a first aspect, a compound or a pharmaceutically acceptable salt or solvate thereof is used to treat a patient infected with a pathogenic organism. In some embodiments, the patient is infected with a schistosoma parasite, suitably wherein the schistosoma parasite is Schistosoma haematobium, Schistosoma japonicum or Schistosoma mansoni.
[0078] In some embodiments, the patient is a human or animal infected with a liver fluke parasite, suitably wherein the parasite is Fasciola hepatica, Fasciola gigantea, Opisthorchis viverrini or Clonorchis sinensis.
[0079] In some embodiments, the patient is a human or animal, suitably an animal, infected with the Fasciola hepatica parasite.
[0080] In some embodiments, the patient is a human or animal infected with a Plasmodium parasite.
[0081] In some embodiments, the patient is infected with a pathogenic bacteria, suitably, wherein the pathogenic bacteria is selected from Staphylococcus aureus, Mycobacterium smegmatis, MRSA, Enterococcus faecalis, Pseudomonas aeruginosa, Staphylococcus epidermidis and Bacillus cereus, suitably selected from Staphylococcus aureus, MRSA or Enterococcus faecalis. Suitably selected from Staphylococcus aureus or MRSA.
[0082] Suitably, the first aspect provides a compound of formula (I) as defined above or a pharmaceutically acceptable salt or solvate thereof for use in treating a patient infected with a pathogenic organism; wherein the pathogenic organism infected by the patient is selected from a parasite selected from Schistosoma japonicum, Fasciola hepatica or Plasmodium parasite, or a pathogenic bacteria selected from Staphylococcus aureus, MRSA or Enterococcus faecalis.
[0083] In some embodiments, the first aspect of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in treating a patient infected with a pathogenic organism; wherein the pathogenic organism infected by the patient is a parasite selected from schistosoma, hepatic parasites or plasmodium parasites, or a pathogenic bacteria selected from Staphylococcus aureus and MRSA:
[0084]
[0085] wherein X and Y are each independently selected from C, N, O and S, provided that at least one of X and Y is N, O or S;
[0086] Where R 1 and R 2 each independently selected from C1-C8 alkyl, C1-C8 alkenyl, aryl, heteroaryl or alkylaryl groups, which may be optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups; or (CO)OR 13 or (CO)NHR 13 Group, where R 13 is selected from the group;
[0087] Wherein Z is selected from -CN, -NO2, -NR 3 R 4 、-NR 5 (CO)R 6 、C1-C4 alkyl、C1-C4 alkoxy、-(CO)WR 12 , hydroxyl, amino, thiol, chloro, fluoro, CF3, CHF2 or CH2F group; wherein W is a chemical bond, N or O, and wherein R 12is selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0088] Where R 3 and R 4 each independently selected from H, C1-C6 alkyl (optionally forming a ring), C1-C6 alkenyl, an aryl group, or a heteroaryl group, which is optionally substituted with one or more of a C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F group; or (CO)OR 14 or (CO)NHR 14 Group, where R 14 is selected from the group;
[0089] Where R 5 Selected from H, C1-C6 alkyl or C1-C6 alkenyl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0090] Where R 6 is selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups; or (CO)OR 15 or (CO)NHR 15 Group, where R 15 is selected from the group;
[0091] Where R 7 and R 8 When present, each is independently selected from H or C1-C4 alkyl;
[0092] Where R 9 , R 10 and R 11 Each independently selected from H, C1-C4 alkyl, C1-C4 alkoxy, -(CO)WR 12 , hydroxyl, amino, thiol, chloro, fluoro, CF3, CHF2 or CH2F group; wherein W is a chemical bond, N or O, and wherein R 12Selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted by one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups.
[0093] According to a second aspect of the present invention, there is provided a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof:
[0094]
[0095] Where R 1 and R 2 independently selected from C1-C8 alkyl, C1-C8 alkenyl, aryl group or alkylaryl group, which may be optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, fluorine, chlorine, CF3, CHF2 or CH2F groups;
[0096] Wherein Z is selected from -NR 3 R 4 or -NR 5 (CO)R 6 ;
[0097] Where R 3 and R 4 Each independently selected from H, C1-C6 alkyl (optionally forming a ring), C1-C6 alkenyl, aryl group or heteroaryl group, which is optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0098] Where R 5 Selected from H, C1-C6 alkyl or C1-C6 alkenyl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0099] Where R 6 is selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted with one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups;
[0100] Where R 7 and R8 Each independently selected from H or C1-C4 alkyl;
[0101] Where R 9 , R 10 and R 11 Each independently selected from H, C1-C4 alkyl, C1-C4 alkoxy, -(CO)WR 12 , hydroxyl, amino, thiol, chloro, fluoro, CF3, CHF2 or CH2F group; wherein W is a chemical bond, N or O, and wherein R 12 Selected from C1-C6 alkyl, C1-C6 alkenyl, aryl or heteroaryl groups, which are optionally substituted by one or more of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylamino, C1-C4 alkylthio, hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F groups.
[0102] The compound of the second aspect, or a pharmaceutically acceptable salt or solvate thereof, may have any suitable features and advantages discussed in relation to the first aspect.
[0103] Suitably, R 1 and R 2 Independently selected from aryl groups or alkylaryl groups, which are optionally substituted with one or more of C1-C4 alkoxy, hydroxy, chloro, fluoro, CF3, CHF2 or CH2F groups.
[0104] Suitably, R 1 and R 2 Independently selected from aryl groups or alkylaryl groups, which are substituted by one or more of methyl, methoxy, hydroxyl, Cl, F or CF3 groups.
[0105] According to a third aspect of the present invention there is provided a compound according to the second aspect for use as a medicament.
[0106] According to a fourth aspect of the present invention there is provided a compound according to the second aspect for use in treating a patient infected with a pathogenic organism.
[0107] The treatment of the fourth aspect may have any suitable features as described in relation to the first aspect.
[0108] According to a fifth aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound according to the first or second aspect or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
[0109] According to the sixth aspect of the present invention, there is provided a method for treating a patient infected with a pathogenic organism, the method comprising administering to the patient a therapeutically effective amount of a compound according to the first or second aspect or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to the fourth aspect.
[0110] The treatment of the sixth aspect may have any suitable features as described in relation to the first aspect.
[0111] According to a seventh aspect of the present invention, there is provided the use of the composition according to the first or second aspect for disinfecting a surface, the surface being, for example, a surface comprising pathogenic bacteria. The use of the seventh aspect suitably comprises, for example, applying the compound or a composition comprising the compound to the surface by spraying. The surface is suitably the surface of an inanimate article. Therefore, this use suitably relates to the in vitro application of a compound or a composition containing the compound on the surface. In some embodiments, before the device or implant contacts living tissue, the surface is the surface of a surgical device or a surgical implant.
[0112] The compound may have any suitable features or advantages as described in relation to the first and second aspects. The pathogenic bacteria may be as described in the first aspect.
[0113] General experimental details
[0114] Reagents, solvents and other general information
[0115] All commercially available solvents and reagents were used as provided by Sigma-Aldrich, Fluorochem or other commercial sources without further purification or treatment. The only exception was compound 2,3-dichloro-6-nitroquinoxaline (product code 49489-Fluorochem, compound 2, MW = 244.03), which also contained compound 3 (6-nitroquinoxaline-2,3-diol, MW = 207.15). This Fluorochem product produced a mixture of compounds 2 and 3 in a ratio of 3:1 according to NMR analysis.
[0116]
[0117] By dissolving 500mg mixture in dichloromethane (DCM, 200ml), and washing four times with sodium hydroxide (NaOH 1N, 20ml for each washing), until no trace of compound 3 is detected using thin layer chromatography (TLC), a purified mixture is obtained. The organic phase is washed once with brine (15ml), then dried with anhydrous Na2SO4, filtered and dried to obtain pure compound 2 (350mg). The alkaline solution (obtained by extraction) is acidified with 6N hydrochloric acid until the pH value is 5. The aqueous solution is then extracted four times with ethyl acetate (EtOAc, 15ml). The combined organic phase is washed with brine, then dried with anhydrous Na2SO4, filtered and dried to obtain pure compound 3 (125mg). The structures of these compounds are confirmed by NMR, and their spectra are consistent with the data reported in the public spectral database.
[0118] The following solvents were purchased in anhydrous form: N,N-dimethylsulfoxide (DMSO) and acetonitrile (CH3CN). Other solvents used herein were: dichloromethane (DCM), ethyl acetate (EtOAc) and n-hexane.
[0119] All glassware was dried in an oven at 130°C for 2 hours and cooled to room temperature before use. Reactions under MWI conditions (microwave irradiation) were performed in a CEM Discover microwave system in closed vessel mode.
[0120] Thin layer chromatography
[0121] All reactions were monitored by thin layer chromatography (TLC) on commercially available Merck Kieselgel 60F254 plates (105554, Merck). TLC was eluted with n-hexane / EtOAc in different ratios, depending on the specific compound synthesized. Ultraviolet light (245 and 366 nm) was used to observe the separated components.
[0122] Flash column chromatography (CC)
[0123] Flash column chromatography was performed on an Interchim PuriFlash 430 using a high performance silica gel column with a 50 micron particle size. The samples were applied to the silica gel as concentrated solutions in DCM (if the sample was not soluble in DCM, EtOAc was used instead). The samples were purified using n-hexane / EtOAc in different ratios depending on the specific compound being synthesized. The fractions containing the desired product were analyzed by TLC, then combined and the solvent removed under vacuum.
[0124] NMR spectroscopy
[0125] Will 1 H and13 C was recorded on a Brucker Avance 500 spectrometer (500 and 126 MHz, respectively) at 25°C. The spectra were calibrated according to the residual signal of the deuterated solvent used (deuterated DMSO-DMSO-d6- was used for all compounds shown in this article). MestReNova (v6.0.2-5475) NMR processing software was used for peak separation and calculation of coupling constants. Chemical shifts δ are expressed in parts per million (ppm) and are rounded to two decimal places. The following abbreviations are used in the NMR signal assignment: s for singlet, br s for broad peak, d for doublet, t for triplet, q for quartet, and m for multiplet. The coupling constant (J) is measured in Hertz (Hz) and is rounded to one decimal place.
[0126] High performance liquid chromatography (HPLC)
[0127] Using a Waters UPLC system with diode array detection and electrospray ionization (ESI) + Purity / quality determination of test compounds was performed using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) analysis with MS detection. The stationary phase was a Waters Acquity UPLC BEH C18 1.7 μm 2.1×50 mm column. The mobile phase was H2O (A) containing 0.1% formic acid and CH3CN (B) containing 0.1% formic acid. The column temperature was 40°C, the sample diluent was acetonitrile, and the sample concentration was 1 μg / mL. The sample injection volume was 2 μL at a flow rate of 0.5 mL / min. The method used included a 3 min run time, isocratic elution at 90% A (0.1 min), followed by a 1.4 min gradient from 10% to 100% B, followed by a 1.4 min isocratic elution at 100% B, followed by a 0.1 min initial condition gradient. The Galaxie Chromatography Data System was used for data analysis.
[0128] All compounds tested in bioassays were >95% pure. Unless otherwise stated, intermediates were >90% pure.
[0129] Preparation of compounds
[0130] Standard Procedure 1a: Preparation of N-(CH2)n Aromatic Analogs of Compound 1
[0131] Under nitrogen atmosphere, an appropriate amount of aniline or phenylalkylamine (5 eq.) was added to a stirred solution of purified 2,3-dichloroquinoxaline (compound 2, 1 eq. -1 eq.) in anhydrous DMSO. The reaction mixture was stirred at 130 ° C for 30 min. The reaction was monitored by TLC with n-hexane / EtOAc (7:3). After the reaction was completed, the mixture was diluted with EtOAc and poured into ice water. The aqueous phase was extracted three times with EtOAc, and the combined organic phases were then washed with 6N hydrochloric acid (4 times) and once with brine solution. The organic phase was then dried over anhydrous Na2SO4, filtered and dried to obtain a crude product. The crude product was purified by flash chromatography (BiotageIsolera One), eluting with n-hexane / EtOAc in different ratios depending on the specific analog synthesized. The procedure provides compounds of general formula (VII):
[0132] Where n is 0, 1 or 2;
[0133] Standard Procedure 1b: Preparation of N-acyl derivatives of compound 1
[0134] Under nitrogen atmosphere, anhydrous pyridine (3.6 eq.) was added to an anhydrous DCM solution of compound 15 (1 eq.). An appropriate amount of acyl derivative (1.1 eq.) was added dropwise to the above solution (cooled to 0°C in an ice bath under nitrogen). The resulting mixture was stirred at room temperature for 1 hour. After completion, the reaction mixture was diluted with DCM and quenched with a saturated sodium bicarbonate (NaHCO3) aqueous solution. The organic phase was first washed with a saturated NaHCO3 aqueous solution (three times) and brine (once). The organic layer was then dried over anhydrous Na2SO4, filtered and dried to obtain a crude product.
[0135] The crude product was purified by flash chromatography (Biotage Isolera One) eluting with n-hexane / EtOAc in varying ratios depending on the specific analog synthesized. This procedure provided compounds of general formula (VIII):
[0136]
[0137] Experimental part and spectral data
[0138] N 2 ,N 3 -Synthesis of bis(3,4-dichlorophenyl)-6-nitroquinoxaline-2,3-diamine (Compound 1)
[0139]
[0140] Chemical formula: C 20 H 11 Cl4N5O2, molecular weight: 495.14
[0141] Compound 1 was prepared according to standard procedure 1a from a solution of 2,3-dichloroquinoxaline 2 (0.50 g, 2.00 mmol) and 3,4-dichloroaniline (1.62 g, 10 mmol) in DMSO (25 ml) stirred at 130 °C for 30 min. After the reaction was completed, the mixture was diluted with EtOAc (20 ml) and poured into ice water. The aqueous phase was extracted with EtOAc (3×10 ml), and the combined organic phases were then washed with 6N hydrochloric acid (4×10 ml) and once with brine (15 ml). The combined organic phases were dried over anhydrous Na2SO4, filtered and the solvent evaporated. The crude product was purified by automated flash column chromatography, eluting with n-hexane:EtOAc 100:0 v / v increasing to 70:30 v / v in 10 column volumes (CV). The final product 1 was obtained as a red powder with a yield of 36%. 1 H NMR (500MHz, DMSO-d6) δ9.52 (s, 2H, 2x NH), 8.34-8.18 (m, 3H, 3x ArH), 8.11 (d, J=8.9Hz, 1H, ArH), 7.87 (m, 2H, 2x ArH), 7.65 (dd, J=8.8, 6.9Hz, 3H, 3x ArH). 13 C NMR (126MHz, DMSO) δ139.65(ArC), 130.95(ArC), 130.57(3x ArCH), 124.98(ArC), 124.50(ArC), 122.26(ArCH), 121.66(ArCH), 121.13(ArCH), 120.82(ArCH), 120.61(ArCH), 119.87(ArCH). UPLC-MS:t R 2.526min. MS (ESI) + m / z calcd 496.14 [M+H] + , experimental value 494.00-496.08-498.02[M+H] + Note: Data are consistent with previously published papers (Jonathan, 2002; Kher et al., 2015).
[0142] N 2 ,N 3 -Synthesis of bis(4-chlorophenyl)-6-nitroquinoxaline-2,3-diamine (Compound 4)
[0143]
[0144] Chemical formula: C 20 H 13 Cl2N5O2, molecular weight 426.26
[0145] According to the standard procedure 1a, compound 4 was derived from a solution of 2,3-dichloroquinoxaline 2 (0.17 g, 0.70 mmol) and 4-chloroaniline (0.45 g, 3.52 mmol) in DMSO (9 ml) and stirred at 130 ° C for 30 min. The post-treatment of the reaction was similar to compound 1. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100: 0 v / v increasing to 70: 30 v / v in 10CV. The final product 4 was obtained as a brown powder with a yield of 41%. 1 H NMR (500MHz, DMSO-d6) δ9.57 (s, 1H, NH), 9.41 (s, 1H, NH), 8.34-8.27 (m, 1H, ArH), 8.10 (dd, J=7.9, 4.2Hz, 1H, ArH) , 7.95 (ddd, J=13.9, 8.7, 1.9Hz, 4H, ArH), 7.64 (ddd, J=9.4, 4.1Hz, 1H, ArH), 7.48 (ddd, J=8.9, 4.0, 1.4Hz, 4H, ArH). 13 C NMR (126MHz, DMSO) δ144.39(ArC), 143.41(ArC), 142.70(ArC), 141.40(ArC), 138.87(ArC), 138.54(ArC), 135.59(ArC), 129.06(4x ArCH), 127.89 (ArCCl), 127.36 (ArCCl), 126.50 (ArCH), 123.49 (2x ArCH), 122.96 (2x ArCH), 121.12 (ArCH), 119.84 (ArCH). UPLC-MS:t R 2.763min. MS (ESI) + m / z calcd 427.26 [M+H] + , experimental value 426.18-428.19 [M+H] + .
[0146] N 2 ,N 3 -Synthesis of bis(3-chlorophenyl)-6-nitroquinoxaline-2,3-diamine (Compound 5)
[0147]
[0148] Chemical formula: C 20 H 13 Cl2N5O2, molecular weight 426.26
[0149] Compound 5 was prepared according to standard procedure 1a from 2,3-dichloroquinoxaline 2 (0.09 g, 0.38 mmol) and 3-chloroaniline (0.24 g, 1.90 mmol) in DMSO (5 ml) and stirred at 130 ° C for 30 min. The post-treatment of the reaction was similar to compound 1. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100: 0 v / v increasing to 70: 30 v / v in 14CV. The final product 5 was obtained as a yellow powder with a yield of 40%. 1 H NMR (500MHz, DMSO-d6) δ9.57 (s, 1H, NH), 9.42 (s, 1H, NH), 8.31 (d, J=2.7Hz, 1H, ArH), 8.17-8.03 (m, 3H, 3x ArH), 7.86 (dd, J=23.1, 8.2Hz, 2H, 2x ArH), 7.68 (d, J=8.8Hz, 1H, ArH), 7.46 (td, J=8.1, 2.5Hz, 2H, 2x ArH), 7.20 (dd, J=11.9, 8.5Hz, 2H, 2x ArH). 13 C NMR (126MHz, DMSO) δ144.04(ArC), 142.92(ArC), 142.20(ArC), 140.96(ArC), 140.82(ArC), 140.69(ArC), 135.04(ArCCl), 132.98(ArCCl), 130.41(3x ArCH), 126.22(ArCH), 123.31(ArCH), 122.88(ArCH), 120.74(ArCH), 120.64(ArCH), 120.09(ArCH), 119.64(ArCH), 119.13(ArCH). UPLC-MS:t R 2.785min. MS (ESI) + m / z calcd 427.26 [M+H] + , experimental value 426.20-428.18[M+H] + .
[0150] N 2 ,N 3 -Synthesis of bis(4-fluorophenyl)-6-nitroquinoxaline-2,3-diamine (Compound 6)
[0151]
[0152] Chemical formula: C 20 H 13 F2N5O2, molecular weight: 393.35
[0153] Compound 6 was prepared from a solution of 2,3-dichloroquinoxaline 2 (0.10 g, 0.41 mmol) and 4-fluoroaniline (0.23 g, 2.05 mmol) in DMSO (5 ml) and stirred at 130 ° C for 30 min according to standard procedure 1a. The post-treatment of the reaction was similar to compound 1. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100:0 v / v increasing to 70:30 v / v in 10CV. The final product 6 was obtained as an orange powder with a yield of 10%. 1 H NMR (500MHz, DMSO-d6) δ9.56 (s, 1H, NH), 9.39 (s, 1H, NH), 8.29 (d, J=2.6Hz, 1H, ArH), 8.1 9 (dd, J=9.1, 5.0Hz, 1H, ArH), 8.10 (d, J=8.9Hz, 1H, ArH), 7.94 (dd, J=16.4, 10.6Hz, 3H, 3x ArH), 7.67-7.60 (m, 1H, ArH), 7.29 (td, J=8.6, 4.3Hz, 4H, 4x ArH). 13 C NMR (126MHz, DMSO) δ176.35 (2x ArC), 143.88(ArC), 143.35(ArC), 142.61(ArC), 141.32(ArC), 135.84(ArC), 135.83(ArC), 135.37(ArC), 126.11(ArCH), 123.86(ArCH), 1 23.79(ArCH), 123.26(ArCH), 123.20(ArCH), 120.69(ArCH), 119.43(ArCH), 115.71(ArCH), 115.67(ArCH), 115.53(ArCH), 115.49(ArCH). UPLC-MS:t R 2.557min. MS (ESI) + m / z calcd 394.35 [M+H] + , experimental value 394.24[M+H] + .
[0154] N 2 ,N 3 -Synthesis of bis(4-fluoro-3-(trifluoromethyl)phenyl)-6-nitroquinoxaline-2,3-diamine (Compound 7)
[0155]
[0156] Chemical formula: C 22 H 11 F8N5O2, molecular weight: 529.35
[0157] Compound 7 was prepared from 2,3-dichloroquinoxaline 2 (0.12 g, 0.49 mmol) and 4-fluoro-3-(trifluoromethyl)aniline (0.44 g, 2.46 mmol) in DMSO (6 ml) by stirring at 130 ° C for 30 min according to standard procedure 1a. The post-treatment of the reaction was similar to compound 1. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100:0 v / v increasing to 70:30 v / v in 10CV. The final product 7 was obtained as a red powder with a yield of 60%. 1 H NMR (500MHz, DMSO-d6) δ9.61 (s, 2H, 2x NH), 8.32 (br s, 2H, 2x ArH), 8.23 (d, J=13.8Hz, 3H, 3x ArH), 8.10 (brs, 1H, ArH), 7.57 (ddd, J=17.4, 11.5, 7.0Hz, 3H, 3x ArH). 13 C NMR (126MHz, DMSO) δ174.16(ArC), 144.17(ArC), 142.96(ArC), 142.25(ArC), 140.72(ArC), 136.27(ArC), 135.96(ArC), 135.04(ArC), 127.22(ArCH), 1 26.74(ArCH), 126.26(ArCH), 124.73(ArC), 123.71(ArC), 120.74(ArCH), 119.81(ArCH), 119.18(ArCH), 118.62(ArCH), 117.80(ArCH), 117.63(ArCH). UPLC-MS:t R 2.801min. MS (ESI) + m / z calculated: 530.35 [M+H] + , experimental value 530.08[M+H] + .
[0158] N 2 ,N 3 -Synthesis of bis(3-fluoro-5-(trifluoromethyl)phenyl)-6-nitroquinoxaline-2,3-diamine (Compound 8)
[0159]
[0160] Chemical formula: C 22 H 11 F8N5O2, molecular weight: 529.35
[0161] Compound 8 was prepared according to standard procedure 1a from 2,3-dichloroquinoxaline 2 (0.09 g, 0.36 mmol) and 3-fluoro-5-(trifluoromethyl)aniline (0.32 g, 1.8 mmol) in DMSO (5 ml) and stirred at 130 ° C for 30 min. The post-treatment of the reaction was similar to compound 1. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100: 0 v / v increasing to 70: 30 v / v in 15 CV. The final product 8 was obtained as an orange powder with a yield of 10%. 1 H NMR (500MHz, DMSO-d6) δ9.71 (br s, 2H, 2x NH), 8.34-8.18 (m, 3H, 3x ArH), 8.10 (d, J=8.9Hz, 1H, ArH), 7.92 (d, J=31.7Hz, 2H, 2x ArH), 7.65 (d, J=9.0Hz, 1H, ArH), 7.33 (dd, J=24.4, 8.3Hz, 2H, 2x ArH). 13 C NMR (126MHz, DMSO) δ163.17(ArC), 161.24(ArC), 147.21(ArC), 144.53(ArC), 1 42.61(ArC), 141.94(ArC), 140.41(ArC), 134.88(ArC), 131.00(ArC), 126.63(A rCH), 124.55(ArC), 122.38(ArC), 121.11(ArCH), 120.20(ArCH), 113.19(ArCH), 112.71(ArCH), 111.02(ArCH), 110.82(ArCH), 110.58(ArCH), 110.36(ArCH). UPLC-MS:t R 2.882min. MS (ESI) + m / z calculated: 530.35 [M+H] + , experimental value 529.98[M+H] + .
[0162] N 2 ,N 3 -Synthesis of bis(2-fluoro-5-(trifluoromethyl)phenyl)-6-nitroquinoxaline-2,3-diamine (Compound 9)
[0163]
[0164] Chemical formula: C 22 H 11 F8N5O2, molecular weight: 529.35
[0165] Compound 9 was prepared from 2,3-dichloroquinoxaline 2 (0.16 g, 0.66 mmol) and 2-fluoro-5-(trifluoromethyl)aniline (0.59 g, 3.3 mmol) in DMSO (5 ml) by stirring at 130 ° C for 30 min according to standard procedure 1a. The post-treatment of the reaction was similar to compound 1. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100:0 v / v increasing to 70:30 v / v in 12CV. The final product 9 was obtained as a yellow powder with a yield of 10%. 1 H NMR (500MHz, DMSO-d6) δ9.63 (br s, 2H, 2x NH), 7.67-7.48 (m, 4H, 4x ArH), 7.26 (dd, J=11.6, 8.3Hz, 1H, ArH), 7.12 (dd, J=20.4, 10.5Hz, 1H, ArH), 6. 93-6.86 (m, 1H, ArH), 6.74-6.67 (m, 1H, ArH), 6.63 (dd, J=8.2, 1.8Hz, 1H, ArH). 13 C NMR (126MHz, DMSO) δ157.91(ArC), 153.77(ArC), 143.90(ArC), 135.84(ArC), 132.90(ArCH), 131.10(ArCH), 128.72(ArCH), 125.29(ArC) , 124.53(ArCH), 122.03(ArCH), 118.78(ArC), 115.49(ArCH), 115.33(ArCH), 115.19(ArCH), 115.03(ArCH), 114.93(ArC), 111.95(ArC). UPLC-MS:t R 2.378min. MS (ESI) + m / z calculated: 530.35 [M+H] + , experimental value 530.05[M+H] + .
[0166] 6-Nitro-N 2 ,N 3 -Synthesis of bis(3-(trifluoromethyl)phenyl)quinoxaline-2,3-diamine (Compound 10)
[0167]
[0168] Chemical formula: C 22 H 13 F6N5O2, molecular weight: 493.37
[0169] Compound 10 was prepared from 2,3-dichloroquinoxaline 2 (0.15 g, 0.61 mmol) and 3-(trifluoromethyl)aniline (0.49 g, 3.1 mmol) in DMSO (8 ml) by stirring at 130 ° C for 30 min according to standard procedure 1a. The post-treatment of the reaction was similar to compound 1. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100:0 v / v increasing to 70:30 v / v in 12CV. The final product 10 was obtained as a yellow powder with a yield of 30%. 1 H NMR (500MHz, DMSO-d6) δ9.74 (s, 1H, NH), 9.60 (s, 1H, NH), 8.36-8.21 (m, 5H, 5x ArH), 8.15 (dd, J=9.0, 2.7Hz, 1H, ArH), 7.73-7.62 (m, 3H, 3x ArH), 7.49 (dd, J=12.8, 7.9Hz, 2H, 2x ArH). 13 C NMR (126MHz, DMSO) δ144.16(ArC), 142.99(ArC), 142.27(ArC), 140.77(ArC), 14 0.29(ArC), 140.02(ArC), 135.04(ArC), 130.01(ArCH), 129.97(ArCH), 129.53( ArC), 126.26(ArCH), 125.32(ArC), 124.64(ArCH), 124.18(ArCH), 120.76(ArCH), 119.86(ArCH), 119.79(ArCH), 119.42(ArCH), 117.28(ArCH), 116.75(ArCH). UPLC-MS:t R 2.344min. MS (ESI) + m / z calcd 494.37 [M+H] + , experimental value 494.15[M+H] + .
[0170] 6-Nitro-N 2 ,N 3 -Synthesis of bis(4-(trifluoromethyl)phenyl)quinoxaline-2,3-diamine (Compound 11)
[0171]
[0172] Chemical formula: C 22 H 13 F6N5O2, molecular weight: 493.37
[0173] Compound 11 was prepared according to standard procedure 1a from 2,3-dichloroquinoxaline 2 (0.20 g, 0.85 mmol) and 4-(trifluoromethyl)aniline (0.69 g, 4.25 mmol) in DMSO (10 ml) and stirred at 130 ° C for 30 min. The post-treatment of the reaction was similar to compound 1. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100:0 v / v increasing to 80:20 v / v in 12CV. The final product 11 was obtained as a yellow powder with a yield of 50%. 1 H NMR (500MHz, DMSO-d6) δ9.74 (s, 1H, NH), 9.61 (s, 1H, NH), 8.34 (s, 1H, ArH), 8.18-8.07 (m, 5H, 5x ArH), 7.77 (d, J=8.3Hz, 4H, 4x ArH), 7.68 (d, J=8.9Hz, 1H, ArH). 13 C NMR (126MHz, DMSO) δ144.22(ArC), 143.16(ArC), 142.87(ArC), 142.79(ArC), 142.07(ArC), 140.67(ArC), 135.03(ArC), 125.90(5x ArCH), 123.06(ArCF3), 122.81(ArCF3), 120.94(3xArCH), 120.42(2xArCH), 119.78(ArCH). UPLC-MS:t R 2.357min. MS (ESI) + m / z calcd 494.37 [M+H] + , experimental value 494.13[M+H] + .
[0174] N 2 ,N 3 -Synthesis of bis(4-methoxy-3(trifluoromethyl)phenyl-6-nitroquinoxaline-2,3-diamine (Compound 12)
[0175]
[0176] Chemical formula: C 24 H 17 F6N5O4, molecular weight: 553.42
[0177] Compound 12 was prepared from 2,3-dichloroquinoxaline 2 (0.16 g, 0.61 mmol) and 4-methoxy-3-(trifluoromethyl)aniline (0.58 g, 3.05 mmol) in DMSO (8 ml) by stirring at 130 ° C for 30 min according to standard procedure 1a. The post-treatment of the reaction was similar to compound 1. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100: 0 v / v increasing to 50: 50 v / v in 10CV. The final product 12 was obtained as an orange powder with a yield of 88%. 1 H NMR (500MHz, DMSO-d6) δ9.50 (s, 1H, NH), 9.34 (s, 1H, NH), 8.28-8.03 (m, 6H, 6x ArH), 7.55 (d, J=8.8Hz, 1H, ArH), 7.35 (d, J=9.1Hz, 2H, 2x ArH), 3.92(s, 3H, CH3), 3.91(s, 3H, CH3). 13 CNMR(126MHz, DMSO) δ153.16(ArC-OCH3), 152.86(ArC-OCH3), 143.68(ArC), 142.99(ArC), 14 2.31(ArC), 141.01(ArC), 135.07(ArC), 132.16(ArC), 131.83(ArC), 126.92(ArCH), 126.53( ArCH), 125.80(ArCH), 124.70(ArCF3), 122.57(ArCF3), 120.35(ArCH), 119.96(ArCH), 119.4 4(ArCH), 119.29(ArCH), 116.73(ArC), 116.50(ArC), 113.37(ArCH), 113.36(ArCH), 56.28(2x CH3). UPLC-MS:t R 2.273min. MS (ESI) + m / z calculated: 554.42 [M+H] + , experimental value 554.13[M+H] + .
[0178] N 2 ,N 3 -Synthesis of dibenzyl-6-nitroquinoxaline-2,3-diamine (Compound 13)
[0179]
[0180] Chemical formula: C 22 H 19 N 5 O2, molecular weight: 385.43
[0181] Compound 13 was prepared according to standard procedure 1a from 2,3-dichloroquinoxaline 2 (0.13 g, 0.51 mmol) and phenylmethylamine (0.27 g, 2.5 mmol) in DMSO (6 ml) and stirred at 130 ° C for 30 min. The post-treatment of the reaction was similar to compound 1. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100:0 v / v increasing to 70:30 v / v in 10CV. The final product 13 was obtained as an orange powder with a yield of 65%. 1 H NMR (500MHz, DMSO-d6) δ8.16 (d, J=2.6Hz, 1H, ArH), 8.09 (t, J=5.2Hz, 1H, NH), 7.97 (dd, J=8.9, 2.7Hz, 1H, ArH), 7.85 (t, J=5.2Hz, 1H, NH), 7.51 (d, J =8.9Hz, 1H, ArH), 7.46-7.39 (m, 4H, ArH), 7.36 (t, J = 7.6Hz, 4H, ArH), 7.30-7.25 (m, 2H, ArH), 4.76 (d, J = 5.2Hz, 2H, CH2), 4.73 (d, J = 5.1Hz, 2H, CH2). 13 C NMR (126MHz, DMSO) δ 145.08 (ArC), 144.39 (ArC), 142.59 (ArC), 141.92 (ArC), 138.68 (ArC), 138.42 (ArC), 135.58 (ArC), 128.43 (2x ArCH), 128.40 (2x ArCH), 128.13(2xArCH), 128.12(2x ArCH), 127.20(ArCH), 127.13(ArCH), 125.04(ArCH), 119.77(ArCH), 118.01(ArCH), 44.50(2x CH2). UPLC-MS:t R 2.186min. MS (ESI) + m / z calcd 386.43 [M+H] + , experimental value 386.32[M+H] + .
[0182] 6-Nitro-N 2 ,N 3 -Synthesis of diphenylethylquinoxaline-2,3-diamine (Compound 15)
[0183]
[0184] Chemical formula: C 24 H 23 N 5 O2, molecular weight: 413.48
[0185] Compound 14 was prepared from a solution of 2,3-dichloroquinoxaline 2 (0.12 g, 0.49 mmol) and 2-phenylethyl-1-amine (0.30 g, 2.5 mmol) in DMSO (6 ml) and stirred at 130 ° C for 30 min according to standard procedure 1a. The post-treatment of the reaction was similar to compound 1. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100:0 v / v increasing to 70:30 v / v in 10CV. The final product 14 was obtained as an orange powder with a yield of 75%. 1 H NMR (500MHz, DMSO-d6) δ8.18 (d, J=2.7Hz, 1H, ArH), 7.97 (dd, J=8.9, 2.7Hz, 1H, ArH), 7.67 (t , J=5.2Hz, 1H, NH), 7.52 (d, J=8.9Hz, 1H, ArH), 7.43 (t, J=5.1Hz, 1H, NH), 7.34-7.26 (m, 8H, 8x ArH), 7.25-7.18 (m, 2H, 2x ArH), 3.73 (td, J=12.6, 6.6Hz, 4H, 2x CH2-N), 2.97 (dd, J=8.1, 6.6Hz, 4H, 2x CH2). 13 C NMR (126MHz, DMSO) δ145.18(ArC), 144.48(ArC), 142.48(ArC), 141.96(ArC), 139.58(ArC), 139.46(ArC), 135.58(ArC), 128.74(2x ArCH), 128.73(2xArCH), 128.39(2x ArCH), 128.38(2x ArCH), 126.20(ArCH), 126.16(ArCH), 125.04(ArCH), 119.83(ArCH), 117.87(ArCH), 42.61(CH2), 42.57(CH2), 34.20(CH2), 34.15(CH2). UPLC-MS:t R 2.271min. MS (ESI) + m / z calcd 414.48 [M+H] + , experimental value 414.35[M+H] + .
[0186] N 2 ,N 3 -Synthesis of bis(3,4-dichlorophenyl)quinoxaline-2,3,6-triamine (Compound 15)
[0187]
[0188] Chemical formula: C 20 H 13 Cl4N5, molecular weight: 465.16
[0189] Under hydrogen atmosphere, a mixture of compound 1 (0.24 g, 0.48 mmol) and 10% Pd / C (0.25 g) was stirred in EtOAc (24 ml) at room temperature for 8 hours. After the reaction was complete, the reaction mixture was filtered through diatomaceous earth. The filtrate was dried with anhydrous Na2SO4, then filtered and dried to obtain a crude product. The crude product was purified by automatic flash chromatography column chromatography, and n-hexane: EtOAc 100:0 v / v was increased to 50:50 v / v elution in 15 CV. The final product obtained was a yellow powder with a yield of 50%. 1 H NMR (500MHz, DMSO-d6) δ9.06 (s, 1H, NH), 8.88 (s, 1H, NH), 8.36 (d, J=2.5Hz, 1H, ArH), 8.14 (d, J=2.6Hz, 1H, ArH), 7.78 (dd, J=8.9, 2.6Hz, 1H, ArH), 7.70 (dd, J=8.9, 2.6Hz, 1H, ArH), 7.61 (d, J=8.8Hz, 1H, ArH), 7.56 (d, J=8.8Hz, 1H, ArH), 7.34 (d, J=8.7Hz, 1H , ArH), 6.83 (dd, J=8.8, 2.5Hz, 1H, ArH), 6.72 (d, J=2.4Hz, 1H, ArH), 5.42 (s, 2H, NH2). 13 C NMR (126MHz, DMSO) δ147.98(ArC), 141.44(ArC), 140.98(ArC), 140.83(ArC), 137.91(ArC), 137.21(ArC), 130.76(ArC), 130.37(2x ArCH), 128.38(ArC), 126.31(ArCH), 122.97(ArC), 122.12(ArC), 120.63(ArCH), 119.83(ArCH), 119.74(ArCH), 118.98(ArCH), 116.86(ArCH), 105.85(ArCH). UPLC-MS:t R 2.66min. MS (ESI) + m / z calcd 466.16 [M+H] + , experimental value 464.07-466.04-468.05[M+H] + .
[0190] N 2 ,N3 -Synthesis of bis(3,4-dichlorophenyl)-6-(pyrrolidin-1-yl)quinoxaline-2,3-diamine (Compound 16)
[0191]
[0192] Chemical formula: C 24 H 19 Cl4N5, molecular weight: 519.25
[0193] Compound 16 was prepared by adding dibromobutane (0.03 g, 0.14 mmol, 2.2 eq.) to a mixed solution of compound 15 (0.03 g, 0.06 mmol, equiv. 1) and anhydrous K2CO3 (0.01 g, 0.07 mmol, 1.1 eq.) in CH3CN (2 ml). The reaction mixture was irradiated at 150°C for 15 min. After complete reaction, the mixture was filtered with EtOAc (20 ml). The resulting organic phase was washed with saturated NaHCO3 aqueous solution (3×5 ml) and brine (10 ml). The organic layer was then dried over anhydrous Na2SO4, filtered and dried to obtain a crude product. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100:0 v / v increasing to 80:20 v / v in 10CV. The final product 16 obtained was a brown powder with a yield of 28%. 1 H NMR (500MHz, DMSO-d6) δ9.12 (s, 1H, NH), 8.97 (s, 1H, NH), 8.27 (d, J=2.6Hz, 1H, ArH), 8 .19 (d, J=2.5Hz, 1H, ArH), 7.94 (dd, J=8.9, 2.5Hz, 1H, ArH), 7.78 (dd, J=8.9, 2.5Hz, 1H, ArH), 7.67 (d, J=8.8Hz, 1H, ArH), 7.62 (d, J=8.8Hz, 1H, ArH), 7.51 (d, J=8.9Hz, 1H, ArH ), 6.93 (dd, J=9.0, 2.6Hz, 1H, ArH), 6.61 (d, J=2.6Hz, 1H, ArH), 3.35 (t, J=6.6Hz, 4H, 2x CH2), 2.04-1.96(m, 4H, 2x CH2). 13C NMR (126MHz, DMSO) δ145.75(ArC), 141.34(ArC), 141.20(ArC), 140.63(ArC), 138 .11(ArC), 136.89(ArC), 131.13(ArC), 131.04(ArC), 130.72(ArCH), 130.58(ArCH ), 128.61(ArC), 126.51(ArCH), 124.09(ArC), 122.91(ArC), 121.69(ArCH), 120. 62(ArCH), 120.43(ArCH), 119.49(ArCH), 114.87(ArCH), 105.12(ArCH), 48.97(2x CH2), 25.01(2x CH2). UPLC-MS:t R 2.707min. MS (ESI) + m / z calculated: 520.25 [M+H] + , experimental value 515.95-518.05-591.13[M+H] + .
[0194] Synthesis of N-(2,3-bis((3,4-dichlorophenyl)amino)quinoxalin-6-yl)acetamide (Compound 17)
[0195]
[0196] Chemical formula: C 22 H 15 Cl4N5O, molecular weight: 507.20
[0197] According to standard procedure 1b, under nitrogen atmosphere, acetyl chloride (0.01g, 0.13mmol) was added dropwise to anhydrous DCM (4ml) solution containing compound 15 (0.06g, 0.12mmol) and anhydrous pyridine (0.03g, 0.43mmol) to prepare compound 17. The resulting mixture was stirred at room temperature for 1 hour. After completion, the reaction was diluted with DCM (10ml) and quenched with saturated NaHCO3 aqueous solution (15ml). The organic phase was washed with saturated NaHCO3 aqueous solution (3×10ml) and brine (15ml) respectively. The organic layer was then dried with anhydrous Na2SO4, filtered and dried to obtain a crude product. The crude product was purified by automatic flash column chromatography, eluting with n-hexane: EtOAc 100:0v / v increased to 50:50v / v in 10CV. The final product 17 obtained was a light yellow powder with a yield of 52%. 1H NMR (500MHz, DMSO-d6) δ10.11 (s, 1H, NH-C=O), 9.23 (s, 1H, NH), 9.15 (s, 1H, NH), 8.31 (d, J=2.5Hz, 1 H, ArH), 8.24 (d, J=2.6Hz, 1H, ArH), 8.00 (d, J=2.1Hz, 1H, ArH), 7.81 (ddd, J=9.3, 6.9, 2.5Hz, 2H, 2x ArH), 7.63 (dd, J=18.7, 8.8Hz, 2H, 2x ArH), 7.58-7.50 (m, 2H, 2x ArH), 2.09 (s, 3H, CH3). 13 C NMR (126MHz, DMSO) δ 168.38 (C=O), 141.15 (ArC), 140.64 (ArC), 140.43 (ArC), 139.82 (ArC), 137.46 (ArC), 136.30 (ArC), 132.18 (ArC), 130.79 (2x ArC), 130.47(ArCH), 130.43(ArCH), 125.78(ArCH), 123.52(ArC), 123.20(ArC), 121.04(ArC H), 120.78(ArCH), 120.05(ArCH), 119.81(ArCH), 118.78(ArCH), 113.96(ArCH), 24.12(CH3). UPLC-MS: t R 2.195min. MS (ESI) + m / z calculated: 508.20 [M+H] + , experimental value 506.10-508.02-510.04[M+H] + .
[0198] Synthesis of N-(2,3-bis((3,4-dichlorophenyl)amino)quinoxalin-6-yl)hexanamide (Compound 18)
[0199]
[0200] Chemical formula: C 26 H 23 Cl4N5O, molecular weight: 563.30
[0201] Compound 18 was synthesized by adding hexanoyl chloride (0.02 g, 0.12 mmol) to anhydrous DCM (5 ml) solution containing compound 15 (0.05 g, 0.11 mmol) and anhydrous pyridine (0.03 g, 0.39 mmol) according to standard procedure 1b under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 1 hour. The post-treatment of the reaction was similar to compound 17. The crude product was purified by automatic flash column chromatography, eluting with n-hexane: EtOAc 100:0 v / v increased to 70:30 v / v in 10CV. The final product 18 obtained was a brown powder with a yield of 66%. 1 H NMR (500MHz, DMSO-d6) δ10.04 (s, 1H, NH-C=O), 9.24 (s, 1H, NH), 9.17 (s, 1H, NH), 8.33 (d, J=2.6Hz, 1 H, ArH), 8.25 (d, J=2.5Hz, 1H, ArH), 8.05 (d, J=2.2Hz, 1H, ArH), 7.82 (ddd, J=13.8, 8.9, 2.5Hz, 2H, 2x ArH), 7.63 (dd, J=18.7, 8.8Hz, 2H, 2x ArH), 7.59-7.51 (m, 2H, 2x ArH), 2.34 (t, J=7.4Hz, 2H, CH2), 1.62 (p, J=7.4Hz, 2H, CH2), 1.36-1.28 (m, 4H, 2x CH2), 0.91-0.86 (m, 3H, CH3). 13 C NMR (126MHz, DMSO) δ 171.39 (C=O), 141.06 (ArC), 140.64 (ArC), 140.44 (ArC), 139.73 (ArC), 137 .48(ArC), 136.28(ArC), 132.13(ArC), 130.80(ArC), 130.43(ArCH), 130.39(ArCH), 125.73(Ar CH), 123.50(ArC), 123.20(ArC), 120.98(ArCH), 120.76(ArCH), 119.99(ArCH), 119.78(ArCH), 118.84(ArCH), 114.01(ArCH), 36.49(CH2), 30.95(CH2), 24.84(CH2), 21.96(CH2), 13.90(CH3). UPLC-MS:t R 2.429min. MS (ESI) + m / z calcd 564.30 [M+H] + , experimental value 562.04-564.08-566.01[M+H]+ .
[0202] Synthesis of N-(2,3-bis((3,4-dichlorophenyl)amino)quinoxalin-6-yl)furan-2-carboxamide (Compound 19)
[0203]
[0204] Chemical formula: C 25 H 15 Cl4N5O2, molecular weight: 559.23
[0205] Compound 19 was prepared by dropping furan-2-carbonyl chloride (0.02 g, 0.14 mmol) into anhydrous DCM (4 ml) solution containing compound 15 (0.06 g, 0.13 mmol) and anhydrous pyridine (0.04 g, 0.47 mmol) according to standard procedure 1b under a nitrogen atmosphere. The resulting mixture was stirred at room temperature for 1 hour. The post-treatment of the reaction was similar to compound 17. The crude product was purified by automated flash column chromatography, eluting with n-hexane: EtOAc 100:0 v / v increased to 70:30 v / v in 10 CV. The final product 19 obtained was a yellow powder with a yield of 55%. 1 H NMR (500MHz, DMSO-d6) δ10.35 (s, 1H, NH-C=O), 9.26 (s, 1H, NH), 9.20 (s, 1H, NH), 8.35 (d, J=2.5Hz, 1H, ArH), 8.26 (d, J=2.5Hz, 1H, ArH), 8.14 (d, J=2.3Hz, 1H, ArH), 7.96 (dd, J=1.8, 0.8Hz, 1H, ArH), 7.83 (dt, J=8.9, 2.0Hz, 3H, 3x ArH), 7.69-7.55 (m, 3H, 3x ArH), 7.39 (dd, J=3.5, 0.9Hz, 1H, ArH), 6.72 (dd, J=3.5, 1.7Hz, 1H, ArH). 13C NMR (126MHz, DMSO) δ156.61(C=O), 147.88(ArC), 146.23(ArCH), 141.57(ArC), 140.97(ArC), 1 40.80(ArC), 140.45(ArC), 137.07(ArC), 136.55(ArC), 133.03(ArC), 131.20(ArC), 130.85(A rCH), 130.83(ArCH), 126.07(ArCH), 123.95(ArC), 123.70(ArC), 121.45(ArCH), 121.26(ArCH ), 120.47(ArCH), 120.28(ArCH), 120.18(ArCH), 115.79(ArCH), 115.20(ArCH), 112.59(ArCH). UPLC-MS:t R 2.297min. MS (ESI) + m / z calculated: 560.23 [M+H] + , experimental value 557.99-559.93-561.85[M+H] + .
[0206] Compounds 20 and 21 having the structures shown below were obtained commercially from SPECS.
[0207]
[0208] Comparative compounds "Comparative Compound 1 (Comp. 1)" (prepared by a method similar to that described above), "Comparative Compound 2 (Comp. 2)" (obtained from Sigma-Aldrich Trading Co., Ltd.) and "Comparative Compound 3 (Comp. 3)" (obtained from Sigma-Aldrich Trading Co., Ltd.) were included in the experiments described as comparative examples. The results produced by these compounds are shown in Table 1 (first two rows). Compound "Comparative Compound 1" has the following structure.
[0209]
[0210] The compound "Comparative Compound 2" is praziquantel, a known drug for treating human schistosomiasis, having the following structure:
[0211]
[0212] The compound "Comparative Compound 3" is triclabendazole (Tbz), which is a known antiparasitic drug having the following structure:
[0213]
[0214] Biological screening
[0215] 72-hour schistosomula drug screening
[0216] S. mansoni (Puerto Rican strain, Naval Medical Research Institute - NMRI) cercariae were collected from infected Biomphalaria glabrata (NMRI) after exposure to light for 2 hours at 26°C and then mechanically transformed into Schistosoma as described in DG Colley, SK Wikel, Schistosoma mansoni: simplified method for the production of schistosomules., Exp. Parasitol. 35 (1974) 44-51. child Newly transformed Schistosoma japonicum larvae were prepared for 72 h high throughput screening (HTS) in 384-well black-edged microtiter plates (PerkinElmer Instruments, Inc., MA, USA) with a final DMSO concentration of 0.625% as described in M. Nur-e-alam, M. Yousaf, S. Ahmed, ES Al-sheddi, I. Parveen, DM Fazakerley, A. Bari, HAGhabbour, MD Threadgill, KCL Whatley, KF Ho, AJ Al-rehaily, Neoclerodane Diterpenoids from Reehal Fatima, Teucrium yemense, J. Nat. Prod. 80 (2017) 1900-1908. The effects of the compounds on 72 hour cultured Schistosoma japonicum larvae were inferred by analyzing the motility and phenotype of the treated Schistosoma japonicum larvae using the image analysis model described in Paveley, R., Mansour, N., Hallyburton, I., Bleicher, L., Alex, E., Mikic, I., Guidi, A., H Gilbert, I., L Hopkins, A., D Bickle, Q in "Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases", PLoS Negl Trop Dis 6(7): e1762 (2012). The data obtained in this manner are shown in the columns labeled "Phenotype", "Motility" and "Average Schistosoma japonicum larvae" in Table 1.
[0217] Juveniles Drug Screening
[0218] Young 3-week-old worms were obtained by perfusing outbred mice (TO or MF-1) that had been percutaneously infected with 4000 cercariae of S. mansoni 3 weeks previously. Screening of young worms (15-20 worms / well) was performed in a 96-well plate format (flat bottom) containing a final volume of 200 μL of medium (DMEM (Gibco, Paisley, UK) supplemented with 10% v / v Hepes (Sigma-Aldrich Trading Ltd., Gillingham, UK), 10% v / v fetal bovine serum (Gibco, Paisley, UK), 0.7% v / v 200 mM L-glutamine (Gibco, Paisley, UK) and 1X v / v penicillin-streptomycin (Thermo Fisher Scientific, UK) as described in Padalino G, Ferla S, Brancale A, Chalmers IW, Hoffmann KF. Int J Parasitol Drugs Drug Resist. 2018 Dec; 8(3): 559-570. The data obtained in this way are shown in the column marked "larvae" in Table 1.
[0219] Adult drug screening
[0220] Mice (MF-1 mice, Harran, UK) were infected with 180 cercariae 7 weeks previously and euthanized by intraperitoneal injection of phenobarbital / heparin solution. Adult worms were recovered by perfusing the portal system and subjected to drug screening as previously described in Padalino G, Ferla S, Brancale A, Chalmers IW, Hoffmann KF. Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):559-570; in Whiteland HL, Chakroborty A, Forde-Thomas JE, Crusco A, Cookson A, Hollinshead J, Fenn CA, Bartholomew B, Holdsworth PA, Fisher M, Nash RJ, Hoffmann KF. Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):465-474; and in Crusco A, Bordoni C, Chakroborty A, Whatley KCL, Whiteland H, Westwell AD, Hoffmann KF. Eur J Med Chem. 2018 May 25; 152: 87-100. The data obtained in this manner are shown in Table 1 in the column labeled "Adults".
[0221] For quantification of adult worms treated with drugs (e.g. reduced activity, paralysis or retardation), two different methods were used as described below. Egg laying sites were noted, eggs were removed and counted using a Sedgewick counting slide.
[0222] WHO scoring function
[0223] Adult worms were scored using the standardized microscopic WHO-TDR scoring system previously described in Ramirez, B., Bickle, Q., Yousif, F., Fakorede, F., Mouries, M.-A., Nwaka, S. in Schistosomes: Challenges in compound screening, Expert Opin Drug Discov. 2007 Oct; 2(s1): S53-61. This scoring system (0-4) recognizes changes in worm motility and is defined according to the following scoring matrix: 0 = no motility, 1 = motility with no visible gastrointestinal peristalsis, 2 = minimal motility (occasionally from the front or rear end of the worm), 3 = slow continuous motility, and 4 = normal motility.
[0224] Worm Analysis GP2 (WormassayGP2)
[0225] A system based on digital image processing has also been used to assess parasite motility after drug treatment and is an improvement on the method previously described by Marcellino C., Gut, J., Lim, K., Singh R., McKerrow, L. and Sakanari, J. Worm Assay: a novel computer application for whole-plate motion-based screening of macroscopic parasites. PLoS Negl Trop Dis. 2012 Jan: 6 (1): e1494. This enables objective verification of the WHO method described above. The data obtained with this quantitative method are shown in the column labeled "Adult" in Table 1.
[0226] Schistosoma mansoni RNAi
[0227] After perfusion of 7-week infected mice, adult worms were recovered and RNAi was performed as previously described in Geyer KK, Munshi SE, Whiteland HL, Fernandez-Fuentes N, Phillips DW, Hoffmann KF. PLoS Pathog. 2018 Jun 28;14(6):e1007107 and Padalino G, Ferla S, Brancale A, Chalmers IW, Hoffmann KF. Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):559-570. Briefly, smp_138030 and non-specific luciferase siRNA duplexes were purchased from Sigma-Aldrich Trading Co., Ltd. (siSmp_138030 = CGUUUGGUCCCAUCGGACA[dT][dT] and UUGUCCGAUGGGACCAAACG[dT][dT]; siLuc = CUUACGCUGAGUACUUCGA[dT][dT] and UCGAAGUACUCAGCGUAAG[dT][dT]). Mixed hermaphroditic adult pairs (for knockdown assessment by quantitative reverse transcription PCR (qRT-PCR)) were cultured at 37°C in an atmosphere of 5% CO2 in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 10,000 units / ml penicillin and 10,000 μg / ml streptomycin, with 70% medium exchange every 48 h. Quantitative reverse transcription-PCR (qRT-PCR) of smp_138030 abundance was performed at 48 h, and adult motility
[39] and egg number were quantified at 168 h. H3K4me levels detected in schistosome histone extracts were assessed at 72 h.
[0228] Quantitative reverse transcription PCR (qRT-PCR)
[0229] After RNAi with siSmp_138030 and siLuc, mixed hermaphroditic worms were cultured for 48 h and then processed for RNA isolation. In brief, worms were homogenized with TissueLyser LT (Qiagen, UK) in TRIzol Reagent (Invitrogen, UK) before total RNA was isolated using Direct-zol RNA kit (Epigentek, UK). cDNA was then generated using SensiFAST cDNA synthesis kit (Bioline), qRT-PCR was performed and data were analyzed as previously described in Padalino G, Ferla S, Brancale A, Chalmers IW, Hoffmann KF. Int J Parasitol Drugs Drug Resist. 2018 Dec; 8 (3): 559-570. The qRT-PCR primers used to amplify smp_138030 (forward primer FW: 5′-GTCTACCGGGTGTTCGACG-3′, reverse primer 5′-TCCAAATCCCGTGCAGC-3′) and the internal standard α-tubulin (SmAT1; forward primer 5′-CGAAGCTTGGGCGCGTCTAGAT-3′, reverse primer 5′-CTAATACTCTTCACCTTCCCCT-3′) were purchased from Sigma-Aldrich Trading Co., Ltd.
[0230] Histone extraction and H3K4 methylation detection
[0231] Drug- or RNAi-treated adult worms were separated by sex and transferred to new microcentrifuge tubes (with snap caps, 2 ml capacity, round bottom). EpiQuik TM Total histones were extracted from these worms using a total histone extraction kit (OP-0006, Epigentek).
[0232] Follow the manufacturer's instructions for using EpiQuik TM The Global Histone H3-K4 Methylation Assay Kit (P-3017-96) measures global histone H3-K4 methylation.
[0233] Newly excysted larvae (NEJ) drug screening
[0234] Fasciola hepatica (F. hepatica) (Italian strain) metacercariae were obtained from the Ridgeway Research Institute, Gloucestershire, UK, and stored at 4° C. Newly excysted larvae (NEJ) were generated from metacercariae according to Dixon et al. and Wilson et al. (Dixon, KE, The physiology of excystment of the metacercaria of Fasciola hepática L. Parasitology, 1966, 56, 431-456.; Wilson, LR, Good, RT, Panaccio, M., Wijffels, GL, Sandeman, RM, Spithill, TW, Fasciola hepatica: Characterization and Cloning of the Major Cathepsin B Protease Secreted by Newly Excysted Juvenile Liver Fluke. Experimental Parasitology 1998, 88, 85-94) based on the optimization introduced into the decystment method.
[0235] After decystation, NEJ were distributed into 24-well tissue culture plates at a density of 25 parasites per well, each well containing 1 mL of preheated NEJ medium. Compounds were added to their respective wells, and NEJ / compound co-cultures were cultured at 37°C for 72 hours in an atmosphere containing 5% CO2, with a final concentration of 10 μM. The effects of drugs on parasite phenotype and motility were scored independently using a scoring matrix, as previously described in Edwards, J., Brown, M., Peak, E., Bartholomew, B., Nash, RJ, Hoffmann, KF, The diterpenoid 7-keto-sempervirol, derived from Lyciumchinense, displays anthelmintic activity against both Schistosoma mansoni and Fasciola hepatica, PLoS neglected tropical diseases 2015, 9, e0003604-e0003604.
[0236] MTT assay of HepG2 cells
[0237] Caucasian hepatocellular carcinoma (HepG2) cells (85011430, Sigma-Aldrich Trading Co., Ltd.) were used to evaluate the apparent toxicity of these anti-infective compounds.
[0238] In brief, HepG2 cells were treated with compounds for 24 h, as previously described in Crusco A, Bordoni C, Chakroborty A, Whatley KCL, Whiteland H, Westwell AD, Hoffmann KF., Eur J MedChem. 2018 May 25; 152: 87-100. Each compound was used to administer to cells at different concentration points: 200, 100, 75, 50, 20, 10 and 1 μM, each in triplicate. Each compound solution was prepared in HepG2 culture medium at a concentration twice the concentration required for the cytotoxicity test (200-2 μM, for 100-1 μM final concentration). According to the predetermined design, 50 μl of the compound solution was added to the corresponding wells of the plate. Culture medium and DMSO controls (also in triplicate) were prepared by adding 50 μl of new culture medium and DMSO (1.25% v / v) without the compound, respectively. A negative control (1% v / v Triton X-100; X100, Sigma Aldrich Trading Co., Ltd.) was also included in each screening. After adding the compound, each plate was incubated for another 20 h, and then MTT reagent (prepared as described in Nur-E-Alam M, Yousaf M, Ahmed S, Al-Sheddi ES, Parveen I, Fazakerley DM, Bari A, Ghabbour HA, Threadgill MD, Whatley KCL, Hoffmann KF, Al-Rehaily AJ, J Nat Prod. 2017 Jun 23; 80(6): 1900-1908) was applied to assess the cytotoxicity of the compound using the MTT method.
[0239] After 20 h of incubation with the test compound, 10 μl (10% final volume) of 12 mM MTT reagent was added to each well. The plates were then incubated for a further 4 h. After incubation, each plate was blotted under laminar flow to remove the MTT-treated medium. 100 μl of DMSO:isopropanol (1:1) solution was then added to each well, and the plates were then incubated at 37°C for 10 minutes. After incubation, each plate was shaken again, and the absorbance was measured at 570 nm. The absorbance readings were corrected based on the average of the wells used as blanks (no cells). In GraphPad Prism 7.02, the CC for calculating the test compound was generated based on the average absorbance of three replicates at each concentration. 50Dose response curves for concentration values.
[0240] The data obtained in this manner are shown in the column labeled "HepG2" in Table 1. The data were also used to calculate the selectivity index (toxicity index) for the activity against Schistosoma japonicum larvae and adults relative to the HepG2 test activity. The last two columns of Table 1 show the selectivity index for Schistosoma japonicum larvae and adults.
[0241] In vitro antimicrobial activity assay
[0242] Escherichia coli - E. coli - ATCC 25922, Staphylococcus aureus - S. aureus - ATCC 29213, Mycobacterium smegmatis - Mycobacterium smegmatis 215-ATCC 700084, MRSA (USA300, ATCC33591, EM RSA), Pseudomonas aeruginosa-ATCC 27853, Staphylococcus epidermidis-NTCT11077, Bacillus cereus strains were used to test all compounds as previously described in "Untargeted metabolomics reveals a new mode of actionof pretomanid (PA-824)", Baptista, Rafael, Fazakerley, David M., Beckmann, Manfred, Baillie, Les and Mur, Luis AJ2018.Scientific Reports 8(1), 2018. Enterococcus faecalis strains - ATCC 29212, NCTC 12201, ATCC 51299; Streptococcus pneumoniae - ATCC 49619, 18778, 21394, 21395; Haemophilus influenza - ATCC 49766, 18391, 17428; Staphylococcus aureus - NCTC 12493, ATCC BAA-077, ATCC 700698, 11051; for testing compounds, as previously described in "Clinical laboratory testing and in vitro diagnostics test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility devices - Part 1: Reference methods for testing the in vitro activity of antimicrobial agents against bacteria involved in infectious diseases. ISO / FDIS All procedures were performed under Biosafety Level 2.
[0243] In vivo screening of anti-schistosomiasis drugs
[0244] The anti-schistosomal efficacy test of the compounds described herein was conducted on a mouse schistosomiasis model using the following procedure. The cercariae of Schistosoma mansoni were prepared by inducing synchronous shedding of infected smooth biumbilical snails by illumination for 40 minutes (in artificial pond water). Mice were percutaneously infected by exposing the tail to 120 cercariae of Schistosoma mansoni per mouse for 45 minutes [Smithers S, Terry R. The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms. Parasitology. 1965; 55 (4): 695-700]. During the 7-week infection period, up to 6 mice were kept in cages.
[0245] At 6 weeks post-infection (day 42 post-infection), mice were orally administered anthelmintics using autoclaved gavage needles. Prior to administration, the gavage needles were dipped in a concentrated solution of sucrose (approximately 1 g / ml) as a refinement to reduce stress-related responses.
[0246] For oral administration, the compound (dry powder) is weighed and prepared in a suitable vehicle (eg 10% DMSO, 20% Kolliphor EL and 70% sterile water). Fresh co-formulations are prepared daily and any remaining are discarded.
[0247] For each selected compound, a certain number of animals (ranging from 3 to 6) were orally dosed (e.g., a dose level of 100 mg / kg in a dose volume of 10 ml / kg). Each mouse was dosed once a day on two non-consecutive days (days 42 and 44 after infection). Each mouse in the control treatment was dosed with vehicle (10% DMSO, 20% BASF castor oil, and 70% sterile water) in a dose volume of 10 ml / kg, following the same dosing interval.
[0248] At the end of treatment (day 48 after infection), mice were perfused after receiving an intraperitoneal administration of an irreversible dose of sodium pentobarbital (100 μl / 10 g body weight) containing a 100 U / ml heparin solution (in 1X PBS). Adult worms of Mansoni were obtained from each mouse by portal vein perfusion with pre-warmed (37°C) perfusion medium (DMEM supplemented with 0.1% 100 U / ml heparin solution (in 1X PBS)). The worms were collected in a sedimentation bottle placed just below the perfused animal. Subsequently, worms were washed first by sedimentation with perfusion medium and then with pre-warmed adult medium (DMEM (Gibco, Paisley, UK) supplemented with 10% v / v FCS (Gibco, Paisley, UK), 1% v / v L-glutamine (Gibco, Paisley, UK), and an antibiotic cocktail (150 units / ml penicillin and 150 μg / ml streptomycin; Gibco, UK)) [as described in Crusco A, Whiteland H, Baptista R, Forde-Thomas JE, Beckmann M, Mur LAJ, et al. Antischistosomal Properties of Sclareol and Its Heck-Coupled Derivatives: Design, Synthesis, Biological Evaluation, and Untargeted Metabolomics. ACS Infectious Diseases. 2019; 5(7): 1188-99; Whatley KCL, Padalino G, Whiteland H, Geyer KK, Hulme BJ, Chalmers IW, et al. The repositioning of epigenetic probes / inhibitors identifies new anti-schistosomal lead compounds and chemomotherapeutic targets. PLOS Neglected Tropical Diseases. 2019;13(11):e0007693; and Whiteland H, Chakroborty A, Forde-Thomas J, Crusco A, Cookson A, Hollinshead J, et al.An Abeis procera-Derived tetracyclic triterpenecontaining a steroid-like nucleus core and a lactone side chain attenuates in vitro survival of both Fasciola hepatica and Schistosoma mansoni.International Journal for Parasitology:Drugs and Drug Resistance.2018;8]. The worm burden per mouse per treatment was quantified after incubation for at least 1 hour at 37°C in a humidified atmosphere containing 5% CO2. .
[0249] After perfusion, the liver was removed and weighed, then placed in a 50 mL centrifuge tube and digested overnight by 4% KOH treatment (37° C.) Each sample was subsequently counted for Schistosoma japonicum eggs (expressed as eggs per organ weight) to assess any differences between drug-treated cages and control cages (e.g., vehicle).
[0250] result
[0251] The data of compounds 1 and 4-21 obtained by the above method were converted into dose-response curves, and the EC of these compounds were calculated based on the average score of each concentration using GraphPad Prism 7.02. 50 Values. Table 1 shows the anti-schistosomal screening data for compounds 1 and 4-21. Table 2 shows the activity of compounds 1, 4, 5, 7, 9-16, 18, 19 and control compound 3 (Tbz) against newly excysted larvae of Fasciola hepatica, against DMSO and RPMI medium controls, where all treatment conditions were statistically evaluated (compared to DMSO controls) using Kruskal-Wallis analysis of variance (followed by Dunn's post-hoc analysis test). Table 3 shows the antibacterial screening data for compounds 2, 5, 7, 10-14 and 16-19. Table 4 shows additional antibacterial screening data for compounds 2, 5, 7, 11, 12 and 19.
[0252] Table 1 shows that the example compounds show similar or improved activity against Schistosoma mansoni juveniles, larvae and adults compared to the comparative compounds "Comparative Compound 1" and "Comparative Compound 2", and many of these compounds show a higher selectivity index than HepG2. Therefore, the compounds of the present invention can provide safe and effective treatment for Schistosoma mansoni infection, and by inhibiting homologous enzymes, can also provide treatment for Fasciola hepatica, Plasmodium falciparum and Staphylococcus aureus infections.
[0253] The data in Table 2 show that the Example compounds exhibited activity against Fasciola hepatica NEJ, which was similar to or improved over the Compound Comparative Compound (Tbz).
[0254] Tables 3 and 4 show that many of the example compounds of the present invention are also effective in combating Staphylococcus aureus and MRSA, and thus can provide effective treatment for infections of these organisms. In addition, the data show that the example compounds can effectively disinfect surfaces, such as surfaces of surgical devices or implants, including pathogenic bacteria, such as Staphylococcus aureus and MRSA.
[0255] Table 1
[0256]
[0257] Table 2
[0258]
[0259] *Phenotypic and motility scores recorded at 72 h are presented as mean scores and standard deviations.
[0260] **All treatment conditions were statistically evaluated (compared to DMSO control) using Kruskal-Wallis ANOVA followed by Dunn's post-hoc analysis test.
[0261] Table 3
[0262] All data points in Table 3 below are MIC90 values in μg / ml.
[0263]
[0264] Table 4
[0265] All data points in Table 4 below are MIC values in mg / l.
[0266]
[0267] Homology modeling and compound docking
[0268] Homology modeling of Smp_138030 (protein lysine methyltransferase) and docking of compound 1 were performed as previously described in Padalino G, Ferla S, Brancale A, Chalmers IW, Hoffmann KF. Int J Parasitol Drugs Drug Resist. 2018 Dec; 8 (3): 559-570. Figure 1 shows the results of molecular docking studies, which support the hypothesized mechanism of action of the compound on protein lysine methyltransferase (Smp_138030). The surface structure of Smp_138030 shows that histones are located in the substrate-binding pocket (highlighted by dotted circles). The binding mode of compound 1 (a representative of the compound family of the present invention) is superimposed on the histones in the substrate-binding pocket, providing support for the hypothesized mechanism of action of these compounds (Part A). In part B, the surface structure of Smp_138030 is hidden to provide a better view of the putative binding mode of the natural substrate (histone) and substrate competitive inhibitor (compound 1).
[0269] Effects of drug treatment on parasite epitopes
[0270] Figure 2 The effect of drug treatment (sublethal concentration of compound 1 - 0.076 μM, sublethal concentration of compound 8 and sublethal concentration of compound 9 - 0.0024 μM) on H3K4 (histone 3, lysine 4) methylation is shown. Figure 2 Showing reduced H3K4 methylation in compound treated worms (male and female, indicated by male and female symbols, respectively). Total H3K4 methylation was significantly reduced by % for each tested compound compared to the negative control (DMSO). However, there were no statistically significant differences between sexes (male and female adults) in the three treatments. Kruskal-Wallis ANOVA and Dunn's multiple comparison test were performed to compare each population mean (mean of three different biological replicates) to the DMSO control. * and ** represent p<0.0163 and p<0.0076, respectively. These data support the hypothesis that these compounds are protein lysine methyltransferase inhibitors.
[0271] RNAi-mediated knockdown of smp_138030 affects worm motility and schistosome egg production in vitro
[0272] Figure 3 and Figure 4Shown how RNAi-mediated knockout of smp_138030 (protein lysine methyltransferase) affects worm movement and in vitro production of schistosome eggs. In Part A, 7-week-old adult male and female schistosomes were electroporated with 5 μg of siRNA duplexes (siLuc) targeting luciferase or siRNA duplexes (siSmp_138030) targeting smp_138030. After 48h, total RNA was collected and qRT-PCR was performed. Compared with the worms treated with siLuc, 60% knockout (KD) of smp_138030 abundance was detected in the worms treated with siSmp_138030. In Part B, five worm pairs (siLuc and siSmp_138030) of each treatment were cultured in an atmosphere of 5% CO2 for 7 days, and 70% of the medium was exchanged every 24h. Quantification of worm motility was performed using the Worm Assay GP2 on day 7, where lower scores indicate lower worm motility (p<0.001). Part C shows daily worm motility of siRNA-treated worms (data on day 3, p<0.01; data from days 4 to 7; p<0.001).
[0273] Part D and Part E ( Figure 4 ) shows the egg laying rate 48h and 168h after the introduction of siRNA, 48h data, p<0.01; 168h data, p<0.001. Part F shows that RNAi-mediated smp_138030 knockdown contains less than 9% H3K4 methylation. After RNAi-induced Smp_138030 knockdown, total histone extracts from RNAi-targeted worms (siSmp_138030) and control worms (siLuc) were analyzed for H3K4 methylation. In siSmp_138030-treated worms, a slight decrease in H3K4 methylation (9%) was found. This data also supports the hypothesis that the compounds of the present invention are protein lysine methyltransferase inhibitors.
[0274] Activity against newly excysted larvae (NEJ) of Fasciola hepatica
[0275] Figure 5The activity of two selected compounds against newly excysted larvae (NEJ) of Fasciola hepatica is shown. Fasciola hepatica NEJ (25 per well) were cultured with three compounds at a concentration of 10 μM (in 0.1% DMSO) and cultured at 37°C in an atmosphere containing 5% CO2 for 72 h. Control wells (25 NEJ per well) included wells containing 0.1% DMSO (solvent) and RMPI (culture medium) as negative controls, or wells containing 10 μM triclabendazole (0.1% DMSO) as positive controls, labeled "Tbz" (comparative compound 3). After 72 h, all NEJ were scored for phenotype and motility. For each treatment, the mean of the phenotypic and motility scores was calculated based on individual parasite scores (across two independent replicates), with higher scores indicating lower worm activity. SD is reported on the bar graph.
[0276] Identification of putative Smp_138030 homologs in other infectious agents
[0277] The protein sequence (Smp_138030) of the putative targets of these compounds was used as a query for protein BLAST (BLASTp) searches against the predicted protein databases of different species genomes from NCBI (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi) and WormbaseParasite (Wormbase-Parasite-a comprehensive resource for helminthgenomics. Howe KL, Bolt BJ, Shafie M, Kersey P and Berriman, M. Mol BiochemParasitol. 2017 Jul;215:2-10) using default settings, except for S. aureus which used a lower threshold and BLOSUM45 as the scoring matrix.
[0278] Table 5 shows the identification of homologous Smp_130830 proteins in Fasciola hepatica, Schistosoma japonicum, S. haematobium, P. berghei, Plasmodium falciparum, Eimeria tenella, Dirofilaria immitis, Haemonchus contortus, Echinococcus multilocularis, and Staphylococcus aureus. The data in Table 5 show the close similarity of the Smp_130830 protein sequence of S. mansoni to the protein lysine methyltransferases of Fasciola hepatica, Eimeria tenella, Dirofilaria immitis, Haemonchus contortus, Echinococcus multilocularis, and Plasmodium listed therein, as well as reasonable similarity to the prmA protein sequence of Staphylococcus aureus. This data indicates that compounds of the present invention, which are believed to be inhibitors of the Smp_138030 enzyme, may also be effective against Fasciola hepatica, Schistosoma japonicum, Schistosoma haematobium, Plasmodium berghei, Plasmodium falciparum, Eimeria tenella, Dirofilaria immitis, Haemotrichum contortus, Echinococcus multilocularis and Staphylococcus aureus due to the inhibitory activity of the homologous proteins identified in Table 5.
[0279] Table 5
[0280]
[0281] *NCBI BlastP
[0282] **WormBase Parasite BlastP
[0283] ADME Data
[0284] Table 6 shows the ADME data for compounds 4, 9, 11, 12, and 18 compared to the listed known control compounds. The data were obtained using the methods described by Cyprotex (https: / / www.cyprotex.com / admepk), the CRO that performed these analyses.
[0285] This data indicates that most of the tested compounds are strongly bound to plasma protein components. In addition, the metabolic stability (in mouse liver microsomes) of most of the tested compounds was classified as moderate (9 to 48 μL / min / mg protein). Finally, most of the compounds were partially soluble (between 1 μM and 100 μM).
[0286] Table 6
[0287]
[0288] ND - Not Determined
[0289] *Compound detected in one of three replicates
[0290] NA - Not Applicable
[0291] SE - Standard Error
[0292] SD - Standard Deviation
[0293] Clint - Intrinsic Clearance
[0294] **Species = mouse, substrate concentration is 1 μM
[0295] fu - the proportion of unbound drug in plasma
[0296] Mouse Pharmacokinetics
[0297] The formulations of compounds 1, 7, 12, 4, 9, 11 and 18 were as follows: 0.25 mg / mL in 10% DMSO, 20% Cremophor EL, 70% water (clear solution). https: / / www.wuxiapptec.com Non-compartmental mouse pharmacokinetics were determined (male C57 / BL6 mice, fasted; 3 mice per group) following oral administration of a nominal 2.5 mg / kg dose of the cassette formulation (5 compounds / group) according to the protocol employed by the CRO that performed these studies.
[0298] The results are shown in Table 7 below.
[0299] Table 7
[0300]
[0301] The results in Table 7 show similar plasma profiles for these compounds, as approximately 3-4 hours after administration (T max ) observed maximum plasma concentrations for each compound (i.e., each compound appeared quickly in the bloodstream). Most interestingly, mice given a single dose of compounds 4, 9, and 11 showed higher C max and AUC 0-last Overall, all compounds were effective within a few hours after administration, as the observed T last (when detectable) was 8 hours after dosing.
[0302] In vivo screening of anti-schistosomiasis drugs
[0303] Figure 6a and 6bThe in vivo worm burden and egg count results of compound 4 obtained using the aforementioned anti-schistosoma in vivo efficacy method are shown respectively. The vehicle used was 10% DMSO, 20% Cremophor EL and 70% water. A 100 mg / kg oral dose of compound 4 was used. Two doses - 100 mg / kg - were administered on day 1 and day 3. Figure 6a and 6b The graphs show that compound 4 induced a 35.5% and 39.9% reduction in worm burden and egg number in vivo, respectively, compared to vehicle.
[0304] These results indicate that compound 4 partially reduced worm and egg burdens in a murine model of experimental schistosomiasis.
[0305] In summary, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in treating a patient infected with a pathogenic organism;
[0306]
[0307] wherein X and Y are each independently selected from C, N, O and S, provided that at least one of X and Y is N, O or S; wherein R 1 and R 2 each independently selected from an optionally substituted C1-C8 alkyl, C1-C8 alkenyl, aryl, heteroaryl or alkylaryl group; and wherein Z is selected from H, -CN, -NO2, -NR 3 R 4 、-NR 5 (CO)R 6 、C1-C4 alkyl、C1-C4 alkoxy、-(CO)WR 12 , hydroxyl, amino, thiol, chlorine, fluorine, CF3, CHF2 or CH2F group. The compound can effectively treat patients infected with parasites selected from schistosoma, liver fluke or plasmodium parasites. In addition or alternatively, the compound of formula (I) can effectively treat patients infected with pathogenic bacteria selected from Staphylococcus aureus and MRSA.
[0308] Unless otherwise limited in specific cases, the following definitions apply to the terms used in this specification.
[0309] As used herein, the term "alkyl" refers to straight and branched saturated hydrocarbon groups. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl and sec-butyl groups. In addition, the term alkyl includes cyclic hydrocarbon groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl groups, etc.
[0310] As used herein, the term "aryl" refers to a carbocyclic aromatic system containing one, two or three rings, wherein the rings may be attached together in a pendant manner or may be fused together. The term "aryl" includes aromatic radicals such as benzyl, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, cycloalkenyl (annulenyl), azulenyl (azulenyl), tetrahydronaphthyl and biphenyl.
[0311] As used herein, the term "heteroaryl" refers to a 3- to 7-membered, preferably 5- to 7-membered, unsaturated heteromonocyclic or fused polycyclic ring, wherein at least one of the fused rings is unsaturated, wherein at least one atom is selected from the group consisting of O, S and N. The term also includes fused polycyclic groups in which heterocyclic radicals are fused to aryl radicals, in which heteroaryl radicals are fused to other heteroaryl radicals, or in which heteroaryl radicals are fused to cycloalkyl radicals. Examples of heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furanyl, thiophenyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuranyl, benzothiophenyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl, etc. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl, etc.
[0312] As used herein, the term "cycloalkyl" refers to a cyclic saturated hydrocarbon group. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
[0313] As used herein, the term "halogen" or "halo" refers to fluorine, chlorine, bromine or iodine. Fluorine and chlorine are particularly preferred.
[0314] "Pharmaceutically acceptable salts" refers to salts such as those described in standard texts on salt formation, see for example: P. Stahl, et a / ., Handbook of Pharmaceutical Salts: Properties, Selection and Use (VCHA / WNey-VCH, 2002), or SM Berge, et al., "Pharmaceutical Salts" (1977) Journal of Pharmaceutical Sciences, 66, 1-19. According to the present invention, suitable salts include those formed with organic or inorganic acids or bases. In particular, according to the present invention, suitable salts formed with acids include salts formed with inorganic acids, strong organic carboxylic acids (e.g. unsubstituted or substituted, for example, by halogen, alkanecarboxylic acids of 1 to 4 carbon atoms, such as saturated or unsaturated dicarboxylic acids, such as hydroxycarboxylic acids, such as amino acids), or with organic sulfonic acids (e.g. unsubstituted or substituted, for example, by halogen, C1-C4 alkylsulfonic acids or arylsulfonic acids). Pharmaceutically acceptable acid addition salts include those formed from hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, citric acid, tartaric acid, acetic acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, trifluoroacetic acid, succinic acid, perchloric acid, fumaric acid, maleic acid, glycolic acid, lactic acid, salicylic acid, oxaloacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, isethionic acid, ascorbic acid, malic acid, phthalic acid, aspartic acid and glutamic acid, lysine and arginine. Other acids which may or may not be pharmaceutically acceptable themselves may be used as intermediates for obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
[0315] Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts (e.g., potassium and sodium salts), alkaline earth metal salts (e.g., calcium and magnesium salts), and salts of organic bases, such as dicyclohexylamine, N-methyl-D-glucosamine, morpholine, thiomorpholine, piperidine, pyrrolidine, mono-, di- or tri-lower alkylamines (e.g., ethyl-propylamine, tert-butyl-propylamine, diethyl-propylamine, diisopropyl-propylamine, triethyl-propylamine, tributyl-propylamine or dimethyl-propylamine), or mono-, di- or trihydroxy lower alkylamines (e.g., mono-, di- or triethanolamine). Corresponding inner salts can also be formed.
[0316] "Pharmaceutically acceptable solvate" refers to a molecular complex comprising a compound of the invention and one or more pharmaceutically acceptable solvent molecules (e.g., water or ethanol). Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they react or from which they precipitate or crystallize. These complexes are referred to as "solvates". For example, complexes with water are referred to as "hydrates". When a pharmaceutical material incorporates a solvent such as water in a stoichiometric or non-stoichiometric amount in the crystal lattice, a solvate, such as a hydrate, exists. Pharmaceutical materials are routinely screened for hydrates because hydrates may appear at any stage of the drug manufacturing process or when the drug material is stored or the dosage form is stored. Solvates are described in S. Byrn et al., Pharmaceutical Research, 1995. 12 (7): p. 954-954, and Water-Insoluble Drug Formulation, 2nd ed. R. Liu, CRC Press, page 553, which are incorporated herein by reference.
[0317] "Therapy," "treatment," and "treating" include both preventative and therapeutic treatment of a condition, disease, or disorder. It also includes slowing, interrupting, controlling, or stopping the progression of a condition, disease, or disorder. It also includes preventing, treating, slowing, interrupting, controlling, or stopping the symptoms of a condition, disease, or disorder.
[0318] While several preferred embodiments have been shown and described, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the scope of the invention as defined in the appended claims.
[0319] Throughout the specification, the term "comprising" or "comprises" means including the specified components, but does not exclude the presence of other components. The term "consisting essentially of" or "consists essentially of" means including the specified components, but excluding other components, except for materials present as impurities, unavoidable materials present as a result of the process for providing the components, and components added for purposes other than achieving the technical effects of the present invention. Typically, when referring to a composition, a composition consisting essentially of a group of components will contain less than 5wt%, typically less than 3wt%, and more typically less than 1wt% of non-specified components.
[0320] The term "consisting of" or "consists of" means including the specified ingredients but excluding the addition of other ingredients.
[0321] Where appropriate, depending on the context, use of the terms “comprise” or “comprising” may also be taken to encompass or include the meaning of “consists essentially of” or “consisting essentially of” and may also be taken to include the meaning of “consists of” or “consisting of.”
[0322] For the avoidance of doubt, where the content of a component in a composition is described in wt %, this refers to the weight percentage of the particular component relative to the entire composition to which it refers.
[0323] Where appropriate, the optional features set forth herein may be used alone or in combination with each other, particularly in the combinations set forth in the appended claims. Where appropriate, the optional features of each aspect or exemplary embodiment of the invention set forth herein should also be understood to be applicable to any other aspect or exemplary embodiment of the invention. In other words, the technician reading this specification should consider the optional features of each exemplary embodiment of the invention to be interchangeable and combinable between different exemplary embodiments.
[0324] Attention is paid to all documents and references filed concurrently or before this specification in connection with this application, which are open to public inspection with this specification, and the contents of all these documents and references are incorporated herein by reference.
[0325] All features disclosed in this specification (including any accompanying claims and drawings) and / or all steps of any method or process as disclosed may be combined in any combination, except combinations where at least some of such features and / or steps are mutually exclusive.
[0326] Unless expressly stated otherwise, each feature disclosed in this specification (including any attached claims and drawings) may be replaced by alternative features for the same, equivalent or similar purpose. Therefore, unless expressly stated otherwise, each feature disclosed is only an example of a series of equivalent or similar features.
[0327] The invention is not limited to the details of the foregoing embodiments. The invention extends to any novel one or any novel combination of the features disclosed in this specification (including any attached claims and drawings), or to any novel one or any novel combination of the steps of any method or process as disclosed.
Claims
1. Use of a compound of formula (III) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a patient infected with a pathogenic organism; (III) Where R 1 and R 2 Each is independently selected from a phenyl group, which is optionally substituted by one or more of a C1-C4 alkoxy, chlorine, fluorine or CF3 group; Wherein Z is selected from -NR 3 R 4 or -NR 5 (CO)R 6 ; Where R 3 and R 4 is a C1-C6 alkyl group forming a ring; Where R 5 Selected from H or C1-C6 alkyl; Where R 6 is selected from C1-C6 alkyl or heteroaryl groups, wherein the heteroaryl group is selected from a 5- to 7-membered unsaturated heteromonocyclic ring in which at least one atom is selected from O and S; Where R 7 and R 8 are each independently selected from H; Where R 9 , R 10 and R 11 are each independently selected from H; The pathogenic organisms infected by the patient are parasites selected from Schistosoma japonicum, Fasciola hepatica or Plasmodium parasites, or pathogenic bacteria selected from Staphylococcus aureus, MRSA and Enterococcus faecalis.
2. The use according to claim 1, wherein Z is -NR 3 R 4 , and where R 3 and R 4 It is a C1-C6 alkyl group forming a ring.
3. The use according to claim 1, wherein Z is -NR 5 (CO)R 6 , where R 5 is H or methyl; where R 6 Selected from C1-C6 alkyl.
